The effect of long-term tafamidis treatment on quality of life in people with transthyretin amyloid cardiomyopathy (ATTR-CM): A plain language summary
Tafamidis slows the worsening of quality of life and heart failure symptoms in people with ATTR-CM. People with ATTR-CM should start treatment early to receive the most benefit.<b>Clinical Trial Registration:</b> NCT01994889 (ATTR-ACT) (ClinicalTrials.gov).
Authors
- Balarama Gundapaneni
- María G. Crespo‐Leiro (ORCID: https://orcid.org/0000-0002-3085-167X)
- Marla B. Sultan
- Mazen Hanna (ORCID: https://orcid.org/0000-0002-7251-3003)
- Margot K. Davis (ORCID: https://orcid.org/0000-0001-7367-8267)
- Franca S. Angeli
- Martha Grogan
Institutions
- Universidade da Coruña (ES)
- Cleveland Clinic (US)
- University of British Columbia (CA)
- Pfizer (United States) (US)
- Centro de Investigación Biomédica en Red (ES)
- Mayo Clinic in Arizona (US)
- Complexo Hospitalario Universitario A Coruña (ES)
- Instituto de Investigación Biomédica de A Coruña (ES)
Publication Details
- Journal
- Future Cardiology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1080/14796678.2024.2391250
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Novo Nordisk
- Astellas Pharma
- Vifor Pharma
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares